See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Semaglutide and Tirzepatide Lead the Way in Comprehensive Diabetes and Obesity Management

Summary by Pharmacy Times
Pharmacists are pivotal in optimizing GLP-1 receptor agonist therapy.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

Stemwell Science NewsStemwell Science News

Modulation of Metabolic, Inflammatory, and Fibrotic Pathways by Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

Scientists show that, in two preclinical metabolic dysfunction-associated steatohepatitis (MASH) models, semaglutide improved histological markers of fibrosis and inflammation and reduced hepatic expression of fibrosis-related and inflammation-related gene pathways. [Nature Medicine] Full Article

Read Full Article
Pharmacy TimesPharmacy Times

Semaglutide and Tirzepatide Lead the Way in Comprehensive Diabetes and Obesity Management

Pharmacists are pivotal in optimizing GLP-1 receptor agonist therapy.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmacy Times broke the news in on Wednesday, July 23, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.

News
For You
SearchBlindspotLocal